NormOxys gets $17.5M to fund PoC work on new drug class

Wellesley, MA-based NormOxys has wrapped a $17.5 million Series B round, which the developer says should be enough to cover the tab for its crucial proof-of-concept work. About a year from now the company should have PoC data for both cancer as well as heart failure, CEO Martin Tolar tells FierceBiotech, offering a much clearer picture of the full potential of its development platform. NormOxys is working on a new class of therapeutics-dubbed oxyrens-which essentially restores the needed level...